IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Ninety One North America Inc.

Ninety One North America Inc. reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,177 shares of the medical research company’s stock after selling 241 shares during the quarter. Ninety One North America Inc.’s holdings in IQVIA were worth $3,193,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in IQV. Morningstar Investment Services LLC boosted its holdings in shares of IQVIA by 2.9% in the first quarter. Morningstar Investment Services LLC now owns 738,821 shares of the medical research company’s stock valued at $140,960,000 after acquiring an additional 20,992 shares in the last quarter. AIA Group Ltd purchased a new stake in shares of IQVIA in the second quarter valued at about $2,808,000. National Asset Management Inc. boosted its holdings in shares of IQVIA by 19.5% in the second quarter. National Asset Management Inc. now owns 5,417 shares of the medical research company’s stock valued at $1,313,000 after acquiring an additional 883 shares in the last quarter. Teacher Retirement System of Texas boosted its holdings in shares of IQVIA by 162.7% in the second quarter. Teacher Retirement System of Texas now owns 95,266 shares of the medical research company’s stock valued at $23,085,000 after acquiring an additional 59,006 shares in the last quarter. Finally, Bridgefront Capital LLC boosted its holdings in shares of IQVIA by 49.9% in the second quarter. Bridgefront Capital LLC now owns 4,153 shares of the medical research company’s stock valued at $1,006,000 after acquiring an additional 1,383 shares in the last quarter. Hedge funds and other institutional investors own 87.01% of the company’s stock.

NYSE:IQV opened at $261.61 on Monday. The firm has a 50 day simple moving average of $254.11 and a 200-day simple moving average of $236.06. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.05 and a quick ratio of 1.05. The firm has a market cap of $50.13 billion, a PE ratio of 83.85, a P/E/G ratio of 2.02 and a beta of 1.42. IQVIA Holdings Inc. has a 1-year low of $146.03 and a 1-year high of $265.34.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 27th. The medical research company reported $2.13 EPS for the quarter, topping the consensus estimate of $2.07 by $0.06. IQVIA had a net margin of 4.69% and a return on equity of 23.95%. The firm had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.27 billion. During the same quarter in the prior year, the business posted $1.18 earnings per share. IQVIA’s revenue for the quarter was up 36.4% compared to the same quarter last year. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 8.25 earnings per share for the current fiscal year.

Several analysts have recently weighed in on IQV shares. Mizuho lifted their target price on shares of IQVIA from $250.00 to $270.00 and gave the company a “buy” rating in a report on Wednesday, July 28th. Citigroup boosted their price objective on shares of IQVIA from $265.00 to $280.00 and gave the stock a “buy” rating in a report on Wednesday, July 28th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of IQVIA from $244.00 to $250.00 and gave the stock a “buy” rating in a report on Wednesday, July 28th. Piper Sandler boosted their price objective on shares of IQVIA from $204.00 to $235.00 and gave the stock a “neutral” rating in a report on Wednesday, July 28th. Finally, Robert W. Baird boosted their price objective on shares of IQVIA from $273.00 to $285.00 and gave the stock an “outperform” rating in a report on Wednesday, July 28th. One research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $262.33.

IQVIA Company Profile

IQVIA Holdings, Inc engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. Technology & Analytics Solutions segment provides mission critical information, technology solutions and real world solutions and services to the firm’s life science clients.

See Also: What is the outlook for the FAANG stocks?

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.